• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

UK study backs Dexcom real-time CGM

May 3, 2023 By Sean Whooley

Dexcom One
The Dexcom One platform. [Image from Dexcom]
Dexcom (Nasdaq:DXCM) announced today that a published study in the UK supports its real-time continuous glucose monitoring (rtCGM).

San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.”

The study produced a long-term health economic analysis using the IQVIA CORE Diabetes Model. This allows the calculation of long-term outcomes based on the best data currently available. It establishes the cost-effectiveness for funding Dexcom rtCGM technology against testing with fingerprints.

According to Dexcom, the analysis suggests that rtCGM use results in significant improvements in HbA1c. It also demonstrated reductions in long-term diabetes-related complications and emergency department visits.

“As healthcare technology – such as Dexcom’s rtCGM Systems – continue to evolve, policymakers have a tremendous opportunity to re-evaluate the standard of care offered to the diabetes community,” said Ben Byrne, country director of UK & Ireland at Dexcom. “Dexcom rtCGM has enormous value, not only in how it can improve quality of life for people managing diabetes, but also because it is likely to save the NHS money.”

Details from the Dexcom study

Key findings included a 70% probability of rtCGM representing a cost-effective option to the NHS compared to fingersticks. The company also observed a 38.7% probability of cost savings for the NHS with rtCGM. The study based this on a willingness-to-pay threshold of £20,000 per quality-adjusted life year.

Additionally, the study associated rtCGM with 0.731 more quality-adjusted life years (QALY). That means the intervention can lengthen and/or improve lives. The study also observed an incremental cost-effectiveness ratio of £3,684 per QALY versus fingersticks.

Patients’ average HbA1c in the study after 12 months of follow-up came in at 8.27%. In the rtCGM group, HbA1c went down by 0.56%. Dexcom observed zero hospitalization events after 12 months.

This analysis piggybacks on previous research that proved Dexcom technology was cost-effective for people with type 1 diabetes in the UK in 2020.

“Our recent analysis clearly adds to the evidence that rtCGM is not only a highly cost-effective intervention for people with diabetes compared to finger pricking but is also likely to be cost saving,” said Byrne. “Given these findings, and with diabetes being so costly to healthcare providers in the UK, we need to take action and mandate more effective glucose monitoring consistently across the NHS and in the UK.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS